Wednesday, July 8, 2026

pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker SUPN. Primary therapeutic focus areas include Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), P

9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
Status
Public
HQ
9715 Key West Ave, Rockville, Maryland 20850, US
Founded
2005
Employees
828
Programs
55
Drugs
25
Patents
68
Clinical program

MYOBLOC Low Dose

Phase 3 · small molecule · Sialorrhea

MYOBLOC Low Dose for Sialorrhea is a Phase 3 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

← All SUPERNUS PHARMACEUTICALS, INC. projects Phase 3 small molecule terminated

Internal code SN-SIAL-302

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
SUPERNUS PHARMACEUTICALS, INC.
Phase
Phase 3
Modality
small_molecule
Indication
Sialorrhea
Status
terminated
Trials
1